| SLE (n = 53) | RA (n = 52) | HD (n = 23) |
---|---|---|---|
Age (years) | 40.9 ± 17.8 | 64.3 ± 15.7 | 38.1 ± 8.0 |
Females, n (%) | 49 (92.5) | 35 (67.3) | 20 (87.0) |
Disease duration (months) | 140.4 ± 159.9 | 83.6 ± 127.1 |  |
SLEDAI score | 4.9 ± 5.4 |  |  |
BILAG score | 4.8 ± 6.6 |  |  |
Anti-dsDNA (U/ml) | 34.4 ± 82.9 |  |  |
IgG (mg/dl) | 1657 ± 710.8 | 1374 ± 396.3 |  |
CH50 (U/ml) | 42.7 ± 14.1 |  |  |
C3 (mg/dl) | 84.7 ± 29.2 |  |  |
C4 (mg/dl) | 16.7 ± 9.1 |  |  |
CRP (mg/dl) | 0.2 ± 0.4 | 1.5 ± 2.0 |  |
ESR (mm/h) | 36.0 ± 31.3 | 42.0 ± 28.1 |  |
Prednisolone use at baseline, n (%) | 36 (67.9) | 18 (34.6) | Â |
Dose of prednisolone (mg/day) | 3.1 ± 3.3 | 3.8 ± 9.6 |  |
Hydroxychloroquine use at baseline, n (%) | 30 (56.6) | Â | Â |
Immunosuppressant use at baseline | |||
 Mycophenolate mofetil, n (%) | 10 (18.9) |  |  |
 Calcineurin inhibitors, n (%) | 9 (17.0) |  |  |
 Azathioprine, n (%) | 4 (7.5) |  |  |
 Methotrexate, n (%) | 2 (3.8) | 36 (69.2) |  |
 Mizoribine, n (%) | 2 (3.8) |  |  |
 Leflunomide, n (%) | 1 (1.9) |  |  |